Milestone launches CARDAMYST nasal spray in US

Milestone Pharmaceuticals Inc. filed a current report describing that it has issued a press release announcing the availability of CARDAMYST (etripamil) nasal spray in the United States.

Rhea-AI Filing Summary

Milestone Pharmaceuticals Inc. filed a current report describing that it has issued a press release announcing the availability of CARDAMYST (etripamil) nasal spray in the United States. The product is indicated for the management of paroxysmal supraventricular tachycardia, a type of rapid heart rhythm. The press release with additional details is included as Exhibit 99.1 and is incorporated by reference into the report.

Insights

Biopharma and SEC disclosure analyst

Milestone highlights US availability of CARDAMYST for PSVT via an attached press release.

Milestone Pharmaceuticals uses this report to formally note that it has issued a press release on the availability of CARDAMYST (etripamil) nasal spray in the United States for managing paroxysmal supraventricular tachycardia. Making a therapy available in a major market like the US often follows prior regulatory clearances, though those details are provided in the referenced press release rather than this summary.

The information here is limited to the fact of availability and the inclusion of the full press release as Exhibit 99.1. There are no sales figures, pricing terms, or revenue guidance in this excerpt, so any business impact would need to be understood by reading the full exhibit and future financial reports.

8-K Event Classification

2 items: 8.01, 9.01

2 items

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does Milestone Pharmaceuticals (MIST) report in this 8-K?

Milestone Pharmaceuticals reports that it has issued a press release announcing the availability of CARDAMYST (etripamil) nasal spray in the United States for managing paroxysmal supraventricular tachycardia.

What is CARDAMYST (etripamil) as described by Milestone Pharmaceuticals (MIST)?

CARDAMYST is described as an etripamil nasal spray indicated for the management of paroxysmal supraventricular tachycardia (PSVT), a type of sudden, rapid heart rhythm.

In which market is CARDAMYST nasal spray now available according to Milestone Pharmaceuticals?

According to the disclosure, CARDAMYST (etripamil) nasal spray is now available in the United States for the management of PSVT.

Where can investors find more details about Milestone Pharmaceuticals’ CARDAMYST announcement?

More details are contained in the company’s press release dated January 26, 2026, which is filed as Exhibit 99.1 and incorporated by reference into the report.

Does this Milestone Pharmaceuticals 8-K include financial or earnings data?

The disclosure focuses on announcing the availability of CARDAMYST nasal spray in the US and listing the related press release as an exhibit, without providing revenue or earnings figures in this excerpt.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 01/26/2026 - 09:27 AM EST Learn about SEC filing dates

false 0001408443 A8 00-0000000 QC 0001408443 2026-01-26 2026-01-26 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):

January 26, 2026

MILESTONE PHARMACEUTICALS INC.

(Exact name of registrant as specified in its charter)

Québec		001-38899		Not applicable
(state or other jurisdiction of incorporation)		(Commission File Number)		(I.R.S. Employer Identification No.)

1111 Dr. Frederik-Philips Boulevard,
Suite 420
Montréal, Québec CA		H4M 2X6
(Address of principal executive offices)		(Zip Code)

Registrant's telephone number, including area code: (514) 336-0444

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

¨     Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨     Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨     Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨     Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Shares		MIST		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b–2 of the Securities Exchange Act of 1934 (§ 240.12b–2 of this chapter).

Emerging growth company ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 8.01 Other Events

On January 26, 2026, Milestone Pharmaceuticals Inc. issued a press release announcing the availability of CARDAMYST (etripamil) nasal spray for the management of paroxysmal supraventricular tachycardia (PSVT) in the United States. A copy of the press release is filed herewith as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits. 

Exhibit Number	Description of Exhibit
99.1	Press Release dated January 26, 2026
104	Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	MILESTONE PHARMACEUTICALS INC.
Date: January 26, 2026	By:	/s/ Amit Hasija
		Amit Hasija
		Chief Financial Officer Principal Financial Officer